MoonLake Immunotherapeutics upgraded by Goldman with a new price target
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $82.00 from $62.00 previously